Suppression of IgE antibody response against ovalbumin by the chemical conjugate of ovalbumin with a polyaspartic acid derivative.
Ovalbumin was modified with alpha,beta-poly[(2-hydroxyethyl)-DL-aspartamide] which had been developed as a nontoxic plasma expander. Preadministration of the modified ovalbumin suppressed both primary and secondary anti-ovalbumin IgE responses.
D000818:Animals; D000917:Antibody Formation; D007114:Immunization; D007073:Immunoglobulin E / Q000276:immunology*; D007165:Immunosuppression Therapy; D051379:Mice; D010047:Ovalbumin / Q000276:immunology*; D010323:Passive Cutaneous Anaphylaxis; D010455:Peptides / Q000276:immunology*; D051381:Rats
D010455:Peptides; C008965:alpha,beta-poly((2-hydroxyethyl)-aspartamide); D007073:Immunoglobulin E; D010047:Ovalbumin